The 4000th eye tumour patient treated with protons at HZB
Overview: Number of patients treated with prontons at HZB from 1998 to 2020. © HZB/S. Kodalle
On 19 February 2021, the 4000th eye tumour patient received irradiation with protons, performed by a joint team from Helmholtz-Zentrum Berlin (HZB) and Charité - Universitätsmedizin Berlin. The number of patients treated in 2020 remained at the previous year's level despite the more difficult corona conditions. The treatment in Berlin-Wannsee is only available for uveal melanomas of the eye. The proton accelerator at HZB is the only therapy site for this disease in Germany.
For more than 20 years, Charité - Universitätsmedizin Berlin and Helmholtz-Zentrum Berlin (HZB) have jointly offered irradiation of eye tumours with protons. For this purpose, the HZB operates a proton accelerator, while the medical care of patients is provided by the Charité.
"We congratulate the joint team on this great success and thank them for doing everything they could under the difficult pandemic conditions to maintain the operation of the life-saving eye tumour therapy," says Prof. Bernd Rech, spokesman for the scientific management of HZB.
500 to 600 people contract malignant uveal melanoma in Germany every year. In 97 percent of cases, the tumour can be completely destroyed by irradiation with protons. In most cases, not only the eye but also the vision can be preserved to a satisfactory degree. Radiation with protons is a particularly effective method: the energy of the proton beam can be adjusted in such a way that practically only the tumour receives the radiation, while the surrounding healthy tissue is spared.
- Strategisches Positionspapier zur Stärkung der SolarindustrieFrankfurt, 06. März 2025 – Die führenden deutschen Solarforschungseinrichtungen, die Fachabteilung „Photovoltaik Produktionsmittel“ des Industrieverbands VDMA und das Produktionsplanungs-Unternehmen RCT Solutions, haben ein gemeinsames Positionspapier zur Stärkung der deutschen und europäischen Solarindustrie veröffentlicht. Dieses wird nun an die Parteien übermittelt, die nach der Bundestagswahl im Bundestag vertreten sind. Ziel ist es, die vorgeschlagenen Maßnahmen in die Koalitionsverhandlungen einzubringen und damit die Grundlage für eine widerstandsfähige und wettbewerbsfähige Solarindustrie in Deutschland zu schaffen.
- Perovskite solar cells: thermal stress is the key to their long term stabilityPerovskite solar cells are highly efficient and low cost in production. However, they still lack stability over the decades under real weather conditions. An international research collaboration led by Prof. Antonio Abate has now published a perspective on this topic in the journal Nature Reviews Materials. They explored the effects of multiple thermal cycles on microstructures and interactions between different layers of perovskite solar cells. They conclude that thermal stress is the decisive factor in the degradation of metal-halide perovskites. Based on this, they derive the most promising strategies to increase the long-term stability of perovskite solar cells.
- Leading Sasol scientist appointed as Industrial Research Fellow at HZBWithin the CARE-O-SENE project, HZB is cooperating with the South African company Sasol on innovative catalysts for sustainable aviation fuels (SAF). Now, the collaboration is intensifying: Dr. Denzil Moodley, a leading scientist in the field of Fischer-Tropsch at Sasol Research and Technology, is being appointed as Industrial Research Fellow at HZB. Moodley will contribute his expertise at HZB with the aim of accelerating the innovation cycle for sustainable fuel technologies.